Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
AI Model Can Optimize, Standardize Total Parenteral Nutrition Formulas
An artificial intelligence (AI) approach identified total parenteral nutrition (TPN) formulas that increase safety and potentially reduce costs for neonates adm
Similar Efficacy Seen for Isodose, Dose-Escalated MHFRT, CFRT in Prostate Cancer
For patients with prostate cancer, isodose and dose-escalated moderately hypofractionated radiotherapy (MHFRT) have similar efficacy as conventionally fractiona
Fasting Outperforms Calorie Cutting, Clinical Trial Says
Fasting every other day can prompt more weight loss than simply cutting calories, a new clinical trial shows. People who undertook 4 3 intermittent fasting lost
GLP-1 Drug Use For Weight Loss Has Soared, Costing Billions
The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says. The number of
Navigators Help Patients Get Colonoscopy For Suspected Cancer
Personalized support can help more people at risk of colon cancer attend a potentially life-saving colonoscopy appointment, a new study says. About 55 of people
Pregnant Women, New Moms Dying More Often From Heart Conditions
The heart-related death rate among pregnant women and new mothers more than doubled between 1999 and 2022, researchers have found. Just under 9.1 mothers for ev
Lilly's Lepodisiran Reduced Levels of Genetically Inherited Heart Disease Risk Factor, Lipoprotein(a), by Nearly 94% from Baseline at the Highest Tested Dose in Adults with Elevated Levels
Eli Lilly and Company (NYSE LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to
AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Significant LDL Cholesterol (LDL-C) Reduction in PURSUIT Phase IIb Trial
Positive results from the PURSUIT Phase IIb trial for AstraZeneca s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C)
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions